Scott Ballentine

Title: Scott Ballentine: Innovator in Pharmaceutical Modulation

Introduction

Scott Ballentine is a notable inventor based in Lansdale, PA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that modulate the TRPM8 receptor. With a total of four patents to his name, Ballentine's work is focused on addressing various medical conditions.

Latest Patents

Among his latest patents are the "Substituted aza-bicyclic imidazole derivatives useful TRPM8 receptor modulators." This invention is directed towards substituted aza-bicyclic imidazole derivatives and pharmaceutical compositions containing them. These compounds are utilized in the treatment of disorders and conditions modulated by TRP M8, including inflammatory pain, neuropathic pain, and cardiovascular diseases aggravated by cold. The second patent, titled "Substituted aza-bicyclic imidazole derivatives useful as TRPM8 receptor modulators," shares a similar focus and application, emphasizing the importance of these derivatives in therapeutic contexts.

Career Highlights

Scott Ballentine is currently employed at Janssen Pharmaceutica NV, where he continues to innovate in the pharmaceutical sector. His work has been instrumental in advancing treatments for various painful conditions, showcasing his commitment to improving patient outcomes through scientific research.

Collaborations

Throughout his career, Ballentine has collaborated with notable colleagues, including Mark R Player and Raul R Calvo. These partnerships have likely contributed to the success and development of his innovative patents.

Conclusion

Scott Ballentine stands out as a significant figure in pharmaceutical innovation, with a focus on TRPM8 receptor modulation. His contributions through patents and collaborations reflect his dedication to advancing medical science and improving therapeutic options for patients.